Chinese biotech company Beijing InnoCare Pharma Tech Co. (InnoCare) has secured a US$160 million new round of financing led by the country’s private equity investment management firm Loyal Valley Capital, according to a statement released on InnoCare’s website on Friday.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register NowAlready have an account or paid subscription? Log in
